| [1] |
Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors-clinical perspectives[J]. Cell Oncol (Dordr), 2021, 44(4): 715-737. DOI: 10.1007/s13402-021-00602-3.
doi: 10.1007/s13402-021-00602-3
|
| [2] |
Zirlik K, Duyster J. Anti-angiogenics: current situation and future perspectives[J]. Oncol Res Treat, 2018, 41(4): 166-171. DOI: 10.1159/000488087.
doi: 10.1159/000488087
pmid: 29562226
|
| [3] |
Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026.
doi: S0378-1119(18)30155-0
pmid: 29454091
|
| [4] |
Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1): 105. DOI: 10.1186/s13045-016-0332-8.
doi: 10.1186/s13045-016-0332-8
|
| [5] |
Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. DOI: 10.1001/jamaoncol.2018.3039.
doi: 10.1001/jamaoncol.2018.3039
pmid: 30098152
|
| [6] |
Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study[J]. Br J Cancer, 2021, 125(3): 366-371. DOI: 10.1038/s41416-021-01356-3.
doi: 10.1038/s41416-021-01356-3
|
| [7] |
Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial[J]. Clin Cancer Res, 2021, 27(13): 3567-3575. DOI: 10.1158/1078-0432.CCR-20-2950.
doi: 10.1158/1078-0432.CCR-20-2950
|
| [8] |
Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018, 24(21): 5233-5238. DOI: 10.1158/1078-0432.CCR-17-3766.
doi: 10.1158/1078-0432.CCR-17-3766
pmid: 29895706
|
| [9] |
Sun Y, Zhou A, Zhang W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase Ⅱ study (ALTER-0802 study)[J]. Hepatol Int, 2021, 15(3): 621-629. DOI: 10.1007/s12072-021-10171-0.
doi: 10.1007/s12072-021-10171-0
|
| [10] |
Chi Y, Shu Y, Ba Y, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase Ⅲ trial (ALTER0703)[J]. Oncologist, 2021, 26(10): e1693-e1703. DOI: 10.1002/onco.13857.
doi: 10.1002/onco.13857
|
| [11] |
Zhou AP, Bai Y, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase Ⅱ clinical trial[J]. Oncologist, 2019, 24(8): e702-e708. DOI: 10.1634/theoncologist.2018-0839.
doi: 10.1634/theoncologist.2018-0839
|
| [12] |
Huang J, Xiao J, Fang W, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. DOI: 10.1002/cam4.3771.
doi: 10.1002/cam4.3771
|
| [13] |
Si X, Zhang L, Wang H, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303[J]. Thoracic Cancer, 2019, 10(3): 551-556. DOI: 10.1111/1759-7714.12977.
doi: 10.1111/1759-7714.12977
pmid: 30666799
|
| [14] |
Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1): 57-77. DOI: 10.3322/caac.21704.
doi: 10.3322/caac.21704
|
)
